Cue Biopharma, Inc.: updates and filings

CUENASDAQHealthcare · Pharmaceutical Preparations

Price

$4.76

November 18, 2026Market cap $50M

What Ploutos Investor adds for Cue Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 66% since Nov 16, 2026, when the 10-Q these figures come from was filed ($14.10 then, $4.76 on Nov 18, 2026). The figures date from before that move.10-Q

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 85 daysAround Feb 12, 2027 · for Q4 2026

last Nov 16, 2026next Feb 12, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 16, 2026 latest annualNov 16, 2026 latest quarterly
  • Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 16, 2026Results of operations
    Form8-K
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 10, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 8, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Sep 21, 2026Regulation FD disclosure, other material events
    Form8-K
  • Aug 21, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • Aug 20, 2026Filing
    FormEFFECT
  • Aug 18, 2026Correspondence with the SEC
    FormCORRESP
  • Aug 17, 2026Letter from the SEC
    FormUPLOAD
  • Aug 14, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 14, 2026Results of operations
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 12, 2026Shelf registration for future offerings
    FormS-3
  • Aug 3, 2026Officer or director change
    Form8-K
  • Jul 22, 2026Filing
    FormD
  • Jul 10, 2026Material agreement entered, unregistered sale of shares, officer or director change, other material events
    Form8-K
  • Jul 1, 2026Filing
    FormEFFECT
  • Jun 29, 2026Correspondence with the SEC
    FormCORRESP
  • Jun 25, 2026Letter from the SEC
    FormUPLOAD
  • Jun 18, 2026Shelf registration for future offerings
    FormS-3
  • Jun 17, 2026Filing
    FormEFFECT
  • Jun 15, 2026Correspondence with the SEC
    FormCORRESP

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 19, 2015.

The full analysis

What do Cue Biopharma's filings show?

The filings are where every one of Cue Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.